Leserbrief
Preliminary outcome of Chelidonium majus (greater celandine) for COVID ‐19
Phytotherapy Research · 2024
DOI: 10.1002/ptr.7776 ↗At a glance
Leserbrief in Phytotherapy Research, 2024. Written by Nilo E Gardin and 1 co-authors. Institution: Brazilian Association of Anthroposophic Medicine, São Paulo, Brazil. Major MEDLINE topics: COVID-19, Chelidonium. 3 references.
Abstract (original language)
Kokkuvõte pole saadaval.
Subjects
MeSH terms (MEDLINE)
COVID-19ChelidoniumHumansChelidonium majus
Authors and institutions
- Brazilian Association of Anthroposophic Medicine, São Paulo, Brazil.
- Brazilian Association of Anthroposophic Medicine, Aracaju, Brazil.
ORCID profiles: Nilo E Gardin
Cite
APA
Gardin, N. E., & Braga, A. J. (2024). Preliminary outcome of Chelidonium majus (greater celandine) for COVID ‐19. Phytotherapy Research. https://doi.org/10.1002/ptr.7776
Vancouver
Gardin NE, Braga AJ. Preliminary outcome of Chelidonium majus (greater celandine) for COVID ‐19. Phytotherapy Research. 2024. doi:10.1002/ptr.7776
BibTeX
@article{Gardin2024,
author = {Gardin, Nilo E and Braga, Anne Jacqueline},
title = {Preliminary outcome of Chelidonium majus (greater celandine) for COVID ‐19},
journal = {Phytotherapy Research},
year = {2024},
doi = {10.1002/ptr.7776}
}
EUVIMED